Skip to main content

Table 3 Baseline characteristics of completers and non-completers of the 3-dose regimen of the quadrivalent HPV vaccine

From: Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls

Characteristic * Completers
(N = 1215)
Non-Completers
(N = 210)
Adjusted OR
(95% CI)
Socio-demographics    
Age (mean ± SD) 13.2 ± 0.3 13.2 ± 0.3 1.02 (0.60-1.75)
Neighbourhood income quintile    
   1 (lowest) 16.9 31.0 0.45 (0.28-0.72)††
   2 17.5 17.6 0.80 (0.48-1.33)
   3 (reference) 21.5 17.1 1.00 (reference)
   4 21.0 16.7 0.98 (0.59-1.62)
   5 (highest) 22.7 16.2 1.15 (0.68-1.92)
   Missing 0.4 1.4 0.56 (0.12-2.66)
Place of residence    
   Urban (reference) 77.7 82.4 1.00
   Rural 21.9 16.2 1.76 (1.14-2.74)††
   Missing 0.4 1.4 0.56 (0.12-2.66)
Vaccination History    
MMR 96.8 92.4 1.61 (0.81-3.19)
Meningococcal C 90.0 79.5 1.39 (0.83-2.35)
Hepatitis B 92.3 81.9 1.67 (0.95-2.92)
All three vaccines§ 85.1 72.4 1.85 (1.29-2.65)††
Health Services Utilisation    
Hospitalizations    
   None (reference) 18.8 23.8 1.00
   1 63.1 54.8 1.23 (0.80-1.91)
   2 12.9 13.8 1.08 (0.59-1.98)
   ≥ 3 5.2 7.6 1.04 (0.45-2.37)
Emergency Department visits    
   None (reference) 26.3 23.3 1.00
   1 21.5 21.9 0.85 (0.53-1.35)
   2-7 43.3 43.8 0.88 (0.58-1.35)
   ≥ 8 8.9 11.0 0.73 (0.38-1.40)
Outpatient visits    
   0-13 (reference) 7.6 13.8 1.00
   14-45 41.2 38.1 1.42 (0.79-2.54)
   46-92 40.7 35.7 1.55 (0.83-2.89)
   ≥ 93 10.5 12.4 1.43 (0.67-3.05)
Medical History    
Previous diagnosis    
   Infectious and parasitic diseases 14.5 19.1 0.83 (0.48-1.42)
   Intestinal infections 3.2 6.7 0.64 (0.28-1.45)
   Chickenpox 1.5 2.4 0.80 (0.25-2.59)
   Cancer 0.9 1.0 0.80 (0.16-3.98)
   Metabolic disorders 3.0 3.3 1.33 (0.50-3.56)
   Disorders of the immune system 0.1 0.0 -
   Diseases of the blood 1.6 0.5 4.60 (0.56-37.84)
   Mental disorders 0.5 0.5 0.84 (0.09-8.36)
   Epilepsy, seizures, and convulsions 3.1 3.8 0.89 (0.38-2.07)
   Gastroenteritis 5.3 7.1 0.70 (0.36-1.37)
   Nephritis 3.5 5.7 0.62 (0.29-1.30)
   Congenital anomalies 7.0 7.1 0.96 (0.52-1.78)
   Syncope 1.2 1.0 1.62 (0.34-7.77)
   Other serious illness 2.1 1.4 1.66 (0.45-6.14)
Immune-mediated events    
   Allergic rhinitis 0.3 0.0 -
   Asthma 5.4 6.7 0.89 (0.46-1.75)
   Dermatitis 4.4 3.3 1.72 (0.72-4.14)
Autoimmune diseases    
   Diabetes mellitus 1.3 1.4 0.77 (0.21-2.83)
   Multiple sclerosis 0.0 0.0 -
   Bell's palsy 0.3 0.0 -
   Guillain-Barré Syndrome 0.0 0.0 -
   Juvenile Arthritis 1.9 3.8 0.58 (0.24-1.41)
   Systemic Lupus Erythematosus 0.0 0.0 -
Risk factors for autoimmune diseases    
   Cytomegalovirus 0.0 0.0 -
   Epstein-Barr virus 0.3 0.0 -
   Campylobacter 0.0 0.0 -
   Influenza 15.9 13.3 1.26 (0.80-1.97)
   Mycoplasma pneumoniae 0.1 0.0 -
  1. OR = Odds Ratio; CI = Confidence Interval; SD = Standard deviation; MMR = Measles, mumps and rubella
  2. * Ascertained anytime preceding cohort entry; expressed as percentages (%) unless otherwise indicated.
  3. † Adjusted for all characteristics listed in table as well as vaccination program year.
  4. †† Statistically significant (p < 0.05).
  5. ‡ Missing because postal code in RPDB was either incorrect or unavailable.
  6. § This variable was defined post-hoc and is adjusted for all factors listed except prior use of the MMR, meningococcal C, and hepatitis B vaccines.
  7. Cut points were based on the frequency distribution of the data for each variable.